Clascoterone: The New Hair Growth Breakthrough

Emerging Hair Restoration Breakthrough: Clascoterone 5% Solution Advances in Phase 3 Trials

Hair loss affects millions worldwide, with androgenetic alopecia (AGA)—commonly known as male pattern baldness—impacting up to 80% of men by age 70. Traditional treatments like topical minoxidil and oral finasteride provide relief for many, but limitations such as variable efficacy, scalp irritation, and potential sexual side effects from systemic DHT blockers drive demand for innovation. Enter clascoterone 5% topical solution: a promising new therapy targeting DHT signaling directly at the scalp with minimal body-wide effects. Recent Phase 3 trial results have dermatologists excited about its potential to reshape non-surgical hair restoration.

Developed by Cosmo Pharmaceuticals (formerly Cassiopea), clascoterone builds on its success as Winlevi® cream for acne vulgaris, where it's FDA-approved as a first-in-class topical androgen receptor inhibitor (ARI). Applied twice daily to the scalp, the 5% solution aims to halt follicle miniaturization and promote regrowth in men with mild-to-moderate AGA (Norwood-Hamilton IIIv to V). As of early 2026, topline data from large-scale trials signal a paradigm shift after decades without new mechanisms.

The Science Behind Clascoterone: Local DHT Blockade Without Systemic Risks

Androgenetic alopecia stems from genetic sensitivity to DHT, a potent testosterone derivative that binds androgen receptors in scalp follicles, triggering progressive thinning at the temples and crown. Oral 5-alpha reductase inhibitors (e.g., finasteride, dutasteride) reduce DHT production body-wide, but up to 15-20% of users report side effects like reduced libido or erectile dysfunction—issues linked to hormonal disruption. Minoxidil, meanwhile, vasodilates follicles but doesn't address the root hormonal cause, yielding modest regrowth in only 40-60% of users.

Clascoterone offers a targeted fix: it competitively binds androgen receptors right where DHT acts—in the dermal papilla of hair follicles—preventing shrinkage without altering circulating hormones. Preclinical studies confirm rapid metabolism in the skin, yielding negligible blood levels (<5 ng/mL peak), far below thresholds for systemic effects. This "hit-and-run" profile minimizes risks such as gynecomastia and mood changes observed with oral ARIs. Early acne trials validated this safety, with common side effects limited to mild application-site erythema (redness) in <10% of users.

Phase 3 Trial Details: SCALP-1 and SCALP-2 Breakdown

The pivotal SCALP-1 (NCT05910450) and SCALP-2 (NCT05914805) trials—the largest topical AGA studies ever—enrolled 1,465 men aged 18+ across 80+ US, European, and Polish sites. Participants had temple/vertex balding (Modified Norwood-Hamilton IIIv-V), ongoing loss, and no recent transplants or prohibited therapies (e.g., minoxidil washout >12 weeks). Randomized 2:1 double-blind (Part 1: 6 months clascoterone vs. vehicle), responders entered single-blind extension (Part 2: another 6 months). Subjects applied ~1.5mL twice daily via dropper, maintaining hairstyles and shampoos.

Co-primary endpoints were:

Target Area Hair Count (TAHC): Non-vellus hairs in a 1-inch circle (macro photos via Canfield imaging).

Patient Global Impression of Change (PGI-C): Self-assessed scalp coverage improvement (score 1-3 for "responder").

Results dazzled: SCALP-1 hit a 539% relative TAHC gain (+15.45 hairs/cm² vs. placebo) at Month 6; SCALP-2 showed 168% (+10.84 hairs/cm²). Combined PGI-C met significance, with ~75% of treated men reporting better coverage—mirroring PRO satisfaction indices. Secondary metrics, such as hair width/darkness improved, and global photos confirmed visible density gains. Variability between trials (common in AGA studies due to baseline and demographic differences) underscores robustness.

Safety mirrored placebo: TEAEs ~25-30%, mostly mild/non-drug-related (headache, nasopharyngitis). No serious scalp issues or systemic signals; ECGs/vitals stable. Long-term Part 2 data (12 months total) due spring 2026, paving FDA/EMA filings. Experts like Maria Hordinsky, MD (University of Minnesota), hail it as "a game-changer for patients avoiding systemic risks.

Comparison to Existing Treatments

Clascoterone edges finasteride in regrowth while slashing sexual side effect risks to near-zero, per modeling. Combo potential (e.g., with low-dose oral) awaits studies.

Regulatory Outlook and Availability

Cosmo targets US/EU approvals post-12-month safety data (Q2 2026). If greenlit, expect TGA review in Australia soon after, given acne precedent. Pricing TBD, but topical convenience (no pills) may boost adherence—key for AGA, where 50% quit finasteride within a year. Watch for head-to-head trials vs. standards.

Patient Considerations: Who Might Benefit?

Ideal candidates: Early-moderate AGA men (20s-50s) seeking non-invasive starts, finasteride-intolerant patients, or combo therapy seekers. Women? Phase 2 hinted promise, but focus remains male. Contraindications mirror trials: active scalp disease and recent PRP/laser therapy. Always pair with lifestyle tweaks—stress reduction, biotin-rich diet, and gentle shampoos.

Luxor Clinic: Supporting Innovation in Melbourne

At Luxor Hair Transplants & Cosmetic Surgery, we support innovation and clinical trials in hair restoration. Our Melbourne team remains abreast of emerging therapies such as clascoterone to offer TGA-compliant, evidence-based options. We integrate medications with transplants and PRP for personalized plans. Curious if this fits you? Schedule your no-cost initial consultation today. It's your scalp—let's restore it with tomorrow's science.

References

1. Dermatology Times: "Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results" (Dec 2025). https://www.dermatologytimes.com/view/clascoterone-5-delivers-strong-phase-3-hair-growth-results[dermatologytimes]
2. ClinicalTrials.gov: NCT05914805 - SCALP-2 Trial. https://clinicaltrials.gov/study/NCT05914805[clinicaltrials]
3. JoinMochi: "Clascoterone SCALP Trial Results." (Dec 2025).[joinmochi]
4. The Derm Digest: "Top-line Phase 3 Data: Clascoterone 5% Solution." (Dec 2025).[thedermdigest]
5. Practical Dermatology: "Clascoterone 5% Solution Achieves Hair Regrowth." (Jan 2026).[practicaldermatology]
6. Business Standard: "A trial drug delivered a 539% boost in hair-growth." (Dec 2025).[business-standard]
7. Bauman Medical: "Clascoterone: A Topical Anti-Androgen For Hair Loss?" (Dec 2025).[baumanmedical]
8. Eleve Studio: Google Advertising Agency Melbourne (contextual TGA reference).[elevestudio.com]